Muse cells and induced pluripotent stem cell: implication of the elite model by unknown
REVIEW
Muse cells and induced pluripotent stem cell: implication
of the elite model
Masaaki Kitada • Shohei Wakao • Mari Dezawa
Received: 6 February 2012 / Revised: 31 March 2012 / Accepted: 5 April 2012 / Published online: 24 April 2012
 The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract Induced pluripotent stem (iPS) cells have
attracted a great deal attention as a new pluripotent stem
cell type that can be generated from somatic cells, such as
fibroblasts, by introducing the transcription factors Oct3/4,
Sox2, Klf4, and c-Myc. The mechanism of generation,
however, is not fully understood. Two mechanistic theories
have been proposed; the stochastic model purports that
every cell type has the potential to be reprogrammed to
become an iPS cell and the elite model proposes that iPS
cell generation occurs only from a subset of cells. Some
reports have provided theoretical support for the stochastic
model, but a recent publication demonstrated findings that
support the elite model, and thus the mechanism of iPS cell
generation remains under debate. To enhance our under-
standing of iPS cells, it is necessary to clarify the properties
of the original cell source, i.e., the components of the
original populations and the potential of each population to
become iPS cells. In this review, we discuss the two the-
ories and their implications in iPS cell research.
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Introduction
In 2006, artificially-induced pluripotent stem (iPS) cells
were reportedly generated from mouse fibroblasts by
introducing exogenous Oct3/4, Sox2, Klf4, and c-Myc (the
so-called Yamanaka factors) [1]. These cells, named iPS
cells, have attracted much attention as a new stem cell type
with potential for medical research and clinical applica-
tions. Although several studies have evaluated the potential
use of human embryonic stem (ES) cells in cell-based
therapy, ethical concerns relating to the use of cells
obtained from embryos limit their practical application.
Thus, iPS cells, which can be generated from somatic cells,
are expected to resolve the problems that pertain to ES
cells [2]. Furthermore, iPS cells from patients with
intractable disease could provide a valuable system for
analyzing the mechanism of disease onset in vitro. Drug
screening using iPS cells is also conceivable. The use of
human ES cells has been limited to certain established clones,
and thus immunologic rejection is considered a major obstacle
for cell therapy, whereas patient-derived iPS cells would be
theoretically free from immunorejection.
The basic characteristics of iPS cells are similar to those
of ES cells; they express pluripotency markers, show self-
renewal, and differentiate into cells representative of all
three germ layers. Like ES cells, iPS cells show unlimited
proliferative activity and form teratomas upon transplan-
tation [3].
Ongoing research, however, has revealed differences
between iPS and ES cells with respect to epigenetic mod-
ification, heterogeneity, and differentiation potential. For
example:
• iPS cells exhibit distinct epigenetic differences from ES
cells that are caused by aberrant methylation during
early passages [4].
• iPS cells harbor residual DNA methylation signatures,
namely ‘‘epigenetic memory’’, characteristic of their
somatic tissue of origin, which favors their differentiation
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along lineages related to the donor cell, while restricting
alternative cell fates [5–7].
• iPS cells obtained from mouse fibroblasts, hematopoi-
etic, and myogenic cells exhibit distinct transcriptional
and epigenetic patterns. Their cellular origin influences in
vitro differentiation potential, and continuous passaging
of iPS cells largely attenuates these differences [4].
• The blood-forming potential of iPS cells derived from
early bone marrow cells is higher than that of iPS cells
derived from neural progenitor cells, whereas the
potential is the same between nuclear transfer-ES cells
and fertilized embryo-derived ES cells [8].
• The same tendency is observed for blood and kerati-
nocyte derivatives. As a consequence of the incomplete
erasure of tissue-specific methylation and aberrant de
novo methylation, umbilical cord blood-derived and
neonatal keratinocyte-derived iPS cells are distinct in
their genome-wide DNA methylation profiles and
differentiation potential; umbilical cord blood-derived
cells have higher potential to differentiate into hema-
topoietic lineage cells, and neonatal keratinocyte-
derived iPS cells have higher potential to differentiate
into keratinocytes [9].
• Epigenetic abnormalities that arise during early repro-
gramming are inherited by iPS cells. These include
hundreds of abnormal gene silencing events, patterns of
aberrant responses to epigenetic-modifying drugs
resembling those of cancer cells, and the presence of
cancer-specific gene promoter DNA methylation alter-
ations [10].
• With regard to a theoretical benefit of immune-toler-
ance in iPS cells derived from autologous cells, a recent
report demonstrated that, in contrast to ES cell deriv-
atives, abnormal gene expression in some cells
differentiated from iPS cells can induce T cell-depen-
dent immune responses in syngeneic recipients [11].
Such characteristics of iPS cells raise a number of
questions. What is the mechanism that underlies the gen-
eration of iPS cells? Why do iPS cells drag epigenetic
memory? How are tumorigenic properties conferred on iPS
cells concomitant with pluripotency? Why is the generation
ratio still very low? Perhaps these questions have their
origin in one more basic question: what is the entity of iPS
cells? This question will be answered by elucidating the
generation mechanism.
To date, two mechanistic theories of iPS cell generation,
the stochastic and the elite models, have been proposed
[12]. The stochastic model purports that every cell type can
potentially be reprogrammed to become an iPS cell by
introducing Oct3/4, Sox2, Klf4, c-Myc, Nanog, and Lin28
[2, 13]; and the elite model proposes that iPS cells can be
generated from only subsets of cells [12]. The correct
model, however, remains an open question, and both
models are conceivable. In any case, the mechanism of iPS
cell generation is still veiled in mystery. At present, the
focus of iPS cell research has moved from advancing their
efficiency to evaluating it in each disease model aiming for
application to cell-based therapy. Before proceeding,
however, the fundamental questions of what iPS cells are
and how are they generated must be addressed. Without
this basic understanding, iPS cell research cannot advance.
This review focuses on the generation of iPS cells and
discusses the entity of iPS cells.
The stochastic model of iPS cell generation
The stochastic model is now broadly accepted. iPS cells
have been generated from various cell sources, such as skin
fibroblasts [2]; keratinocytes [14]; mesenchymal cells from
fat tissue [15], oral mucosa [16] and dental pulp [17]; cord
blood cells [18]; and peripheral blood cells [19] in humans;
and are therefore considered to be generated from any cell
types. Likewise, T cells are reported to be a source for iPS
cells so that even differentiated peripheral blood cells can
be reprogrammed to iPS cells [20]. Jaenisch and colleagues
argued that the existence of distinct cell division rate-
dependent and -independent modes accelerates the sto-
chastic course of reprogramming and that the number of
cell divisions is a key parameter driving epigenetic repro-
gramming to pluripotency, and thus that, theoretically,
almost all mouse donor cells eventually give rise to iPS
cells with continued growth and transcription factor
expression [13]. Other investigators have focused on epi-
genetic regulation after establishing iPS cells. Nishino et al.
[21] reported that stochastic de novo methylation of
genomic DNA occurs, and that cell division proceeds in
established iPS cells after prolonged culture, leading to a
cell condition that epigenetically more closely resembles
that observed in ES cells, suggesting that iPS cell genera-
tion is regulated by such stochastic epigenetic events.
While these reports theoretically and logically support the
stochastic model of iPS cell generation, rigorous proof that
all cell types including fully differentiated cells are, in a
strict sense, able to become iPS cells is still awaited.
Mesenchymal stem cells (MSCs) as a source of iPS cells:
their heterogeneity and diversity
Fibroblasts are the most popular original cell source for
generating iPS cells [1, 2]. They are usually collected from
adherent dermal cell cultures. Histologically, however, the
dermis comprises various cell types; although fibroblasts
are the major component of the connective tissue, blood
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vessel-associated cells such as endothelial cells and peri-
cytes are also at least present in the dermis. Furthermore,
the adult dermis contains several types of stem or pro-
genitor cells, such as skin-derived precursors, neural crest-
derived stem cells, melanoblasts, perivascular cells, endo-
thelial progenitors, and adipose-derived stem cells [22–29].
Therefore, while cells cultured from the dermis mainly
contain authentic fibroblasts, many other cell types are
included. In fact, primary cultured dermal cells subjected to
subculture contain cells positive for CD117 (a marker for
melanoblasts), CD146 (perivascular cells and adipose-
derived stem cells), CD271 (neural crest-derived stem
cells), Snai1 (skin-derived precursors), and Slug (skin-
derived precursors) [30]. Thus, dermal fibroblasts are
actually not a single cell type, but rather comprise heter-
ogeneous cell populations.
This is the same for another mesenchymal tissue, bone
marrow. Bone marrow-derived mesenchymal cells (often
called bone marrow mesenchymal stem cells; BM-MSCs)
are usually collected as adherent cells from bone marrow
aspirates and are also heterogeneous. Pittenger et al. [31]
were the first to analyze the cell surface antigens of BM-
MSCs in detail. Like human fibroblasts, BM-MSCs are
uniformly positive for SH2, SH3, CD29, CD44, CD71,
CD90, CD106, CD120a, CD124, and many other surface
antigens, but negative for markers of the hematopoietic
lineage, including a monocyte antigen CD14, a hemato-
poietic progenitor cell antigen CD34, and the leukocyte
common antigen CD45 [31, 32].
Like fibroblasts and BM-MSCs, MSCs are generally a
crude cell population because they are usually harvested as
adherent cells from mesenchymal tissues such as the der-
mis, bone marrow, adipose tissue, and umbilical cord.
Overall, MSCs express mesenchymal markers, but detailed
analyses reveal that the marker content and expression
ratios differ among these cells. Therefore, it must be kept in
mind that mesenchymal cells, even commonly used fibro-
blasts, often differ with regard to their origin, phenotype,
and differentiation state. As a consequence, when MSCs
are targeted for iPS cell generation, the basic cell popula-
tion is heterogeneous in the potential to become iPS cells.
When culturing cells from other organs and tissues other
than mesenchymal tissues (e.g., peripheral nerve, muscle,
liver, and kidney), fibroblasts are easily mixed into the
primary culture. Even in immune systems such as the
spleen, primary cultured cells are not free from fibroblasts.
In other words, contamination of mesenchymal cells is
unavoidable and collection of a single population is not
guaranteed unless the cells are strictly labeled by cell
surface markers and collected by cell sorting. Further,
histologically, almost all organs contain connective tissue,
and therefore mesenchymal cells will easily penetrate into
the primary culture from any organ harvested. It is not
surprising that even peripheral blood is not free from
mesenchymal cells because several studies have demon-
strated that MSCs with multilineage differentiation ability
appear in the blood under many circumstances such as
disease or injury [33–37].
Hochedlinger’s group suggested that the differentiation
stage of the starting cell influences the efficiency of
reprogramming into iPS cells [4]. They tested the potential
of mouse hematopoietic cells at different stages of differ-
entiation to be reprogrammed into iPS cells and
demonstrated that hematopoietic stem and progenitor cells
give rise to iPS cells with much higher efficiency than do
terminally differentiated B cells. Another report suggested
that many adult tissues contain tissue stem cells that
already express pluripotency markers such as Oct3/4, and
that those cells contribute to iPS cell generation [38, 39].
As these papers suggest, cells in an undifferentiated state
are better able to generate iPS cells.
A problem in the current iPS cell research is that in most
cases experiments are conducted using a mixture of cells with
different stages, potential, and origin. The generation ratio of
iPS cells is still very low, and only a small number of cells
develop into iPS cells. In such circumstances, the signal
coming from cells truly attempting to become iPS cells will be
drowned out by the noise of background cells, making it dif-
ficult to unveil the actual mechanism of iPS cell generation.
There are some reports that iPS cells are successfully
generated by reprogramming terminally differentiated cells.
Although iPS cells appear to be generated from terminally
differentiated cells from various organs such as the liver [40],
spleen [41], or peripheral blood [20], these results may not, in
a strict sense, rule out the possibility that iPS cells are gener-
ated from cells other than terminally differentiated cells unless
those terminally differentiated cells are strictly identified and
selected, e.g., using FACS, before subjecting the cells to the
iPS cell-generation procedure.
Definition of pluripotent stem cells
A ‘‘pluripotent’’ cell is defined as that having the ability to
give rise to cell types of all three embryonic germ layers,
namely endodermal, mesodermal, and ectodermal cells
[42]. In the case of ‘‘pluripotent stem cells’’, the concept
‘‘stem cell’’ applies not only to the differentiation potential
but also the ability to self-renew. In many cases, pluripo-
tent stem cells show germline transmission and/or teratoma
formation in addition to the above two requirements, mim-
icking normal development [42, 43]. Epiblast stem cells,
however, a type of pluripotent stem cell, do not form teratomas
under certain circumstances [44]. Therefore, pluripotent stem
cells do not always meet the strict requirements of teratoma
formation or germline transmission.
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On the other hand, MSCs differentiate into a broad
spectrum of cells that crosses the oligolineage boundaries
between mesodermal and ectodermal or endodermal lin-
eages [45]. Some of the cell types that belong to
mesenchymal tissues, such as neural crest-derived stem
cells and skin-derived precursors, show diploblastic dif-
ferentiation (mesodermal- and ectodermal-lineage cells),
and such differentiation ability is called ‘multipotency’
[23, 28]. Although there are a few reports demonstrating
that a subpopulation of MSCs generate cells representative
of all three germ layers, the term multipotency is not
adequate to describe the high differentiation ability of these
cells. In fact, such cells are often called ‘pluripotent’ to
describe their high differentiation ability [46–49]. In
summary, the abilities of self-renewal and differentiation
into cells representative of all three germ layers are
essential and common requirements for pluripotent stem
cells, and these two properties are sufficiently compre-
hensive to represent their high differentiation ability rather
than setting limits by including germline transmission and/
or teratoma formation abilities. Therefore, in this review,
we define ‘‘pluripotent stem cells’’ as cells having the
ability to self-renew and to differentiate into cells repre-
sentative of all three germ layers.
Mesenchymal cells contain pluripotent stem cells
In general, tissue stem cells generate the cell types of the
tissue in which they reside, and thus the range of their
differentiation capabilities is usually limited. For example,
hematopoietic stem cells generate blood cells and neural
stem cells generate neurons and glial cells [50–52]. MSCs
differ from other tissue stem cells in that they differentiate
not only into the same mesodermal-lineage, such as bone,
cartilage, and adipocytes, but also into other lineages,
ectodermal and endodermal cells.
When MSCs are treated with a certain sets of cytokines
or with transient gene introduction, they differentiate in
vitro into cell types including endothelial cells [53], cardiac
muscle [54], skeletal muscle [55], hepatocytes [56], neu-
ronal cells [57], peripheral glial cells [58], insulin-
producing cells [59], and epithelial cells [60]. The broad
spectrum of differentiation observed in MSCs does not
occur in a high ratio, and thus the cells responsible for
differentiation were considered to comprise a subpopula-
tion of MSCs. Differentiation of MSCs into hepatocytes
[61], keratinocytes [37], and cardiac muscles [62] is also
recognized in vivo in disease models, albeit with a very
low frequency. These observations lead us to speculate that
MSCs contain a subpopulation of pluripotent cells.
Recently, adult human mesenchymal cells such as BM-
MSCs and dermal fibroblasts were shown to contain
pluripotent stem cells that were named multilineage-dif-
ferentiating stress-enduring (Muse) cells [32]. These cells
can be isolated as cells that are double-positive for the
pluripotency marker stage-specific embryonic antigen-3
(SSEA-3, a marker for undifferentiated human ES cells)
and for a mesenchymal marker CD105. When a single
Muse cell was cultured in suspension, the cell began to
proliferate and form a cell cluster resembling an embryoid
body of ES cells. The cluster expressed the pluripotency
markers SSEA-3, Nanog, Oct3/4, and Sox2 and was posi-
tive for alkaline phosphatase, and cells in the cluster
differentiated into endodermal-, ectodermal-, and meso-
dermal-lineage cells when cultured on the gelatin-coated
dish [32] (Fig. 1).
Although the existence of pluripotent cells in MSCs has
long been suggested, to date there have been no reports clearly
demonstrating self-renewal and differentiation potency at a
single cell level, so that the pluripotency in MSCs has
remained controversial [63, 64]. Most importantly, single
Muse cells are able to generate cells representative of all three
germ layers: mesodermal-lineage (osteocytes, adipocytes,
chondrocytes, skeletal muscle cells, smooth muscle cells),
ectodermal-lineage (neuronal cells, glial cells, epidermal
cells), and endodermal-lineage (hepatocytes, biliary system
cells), and they self-renew for up to five generations; thus, they
are pluripotent stem cells [32] (Fig. 1).
ES cells and iPS cells are pluripotent stem cells that form
teratomas upon transplantation. It is noteworthy that, in
contrast to these pluripotent stem cells, Muse cells do not
undergo tumorigenic proliferation, and do not develop into
teratomas when transplanted into immunodeficient mouse
testes [32]. Consistently, while ES cells and iPS cells have
high telomerase activity, Muse cells have low telomerase
activity similar to somatic cells such as fibroblasts. Genes
related to cell-cycle progression are extensively upregulated
in human ES and iPS cells, but in Muse cells they are
expressed at the same level as in naive fibroblasts [30]. The
non-tumorigenicity of Muse cells seems to be consistent with
the fact that they reside in normal adult mesenchymal tissue.
The ratio of Muse cells is \1 % in cultured BM-MSCs
and 2–5 % in commercially obtained fibroblasts, but it is
very low in the fresh human bone marrow mononucleated
cell fraction (1 of 3,000 mononucleated cells) [32].
Immunohistochemistry experiments demonstrated that
Muse cells locate sparsely in the connective tissues of
organs and do not associate with any particular structure
such as blood vessels [30].
The elite mechanistic model of iPS cell generation
In parallel with the stochastic model, it is argued that iPS
cells are the result of the procurement of tumorigenic
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proliferative activity in adult stem cells [65–69]. This,
however, has not been fully investigated. Byrne et al. [67]
reported that only SSEA-3-positive human dermal fibro-
blasts cells can generate iPS cells, but the characteristics of
the original SSEA-3-positive cells were not fully evaluated.
Therefore, the process of iPS cell generation from this cell
population remains obscure, particularly with regard to
whether these cells acquired the abilities of self-renewal
and differentiation into cells representative of all three
germ layers only after transduction of the four Yamanaka
factors or whether they originally possessed these abilities.
A recent report suggested that, at least in the case of
human fibroblasts, iPS cells are generated only from plu-
ripotent Muse cells, which supports the elite model [30].
As mentioned, Muse cells reside in human mesenchymal
tissues and mesenchymal culture cells and exhibit the
characteristic properties of pluripotent stem cells, although
they do not show tumorigenic properties. Interestingly,
when Muse cells were removed from human dermal
fibroblasts, the remaining cell population was unresponsive
to the Yamanaka factors and failed to generate iPS cells
[30]. When human fibroblasts were separated into Muse
cells and non-Muse cells, and each population was sub-
jected to the iPS cell generation procedure, iPS colonies
were only generated from Muse cells and not from non-
Muse cells. Just prior to colony pickup, both populations
formed colonies with various morphologic features, but
only the Muse cell population produced colonies with a
human ES cell-like morphology that were positive for the
human pluripotent stem cell marker TRA-1–81, a marker
for promising iPS colonies [70], while non-Muse cells
generated no TRA-1–81-positive colonies and all the col-
onies from non-Muse cells were unlike human ES cells. All
the cells and colonies of each population were collected
and subjected to reverse transcription-polymerase chain
reaction (RT-PCR), which detected endogenous Sox2 and
Nanog, the fundamental transcriptional regulators of plu-
ripotent stem cells in cells and colonies derived from Muse
cells, but never in those derived from non-Muse cells [30]
(Fig. 2). Colonies generated from Muse and non-Muse cells
were further picked up and passaged in individual wells to
establish iPS cell lines. Only colonies picked from Muse cells
established iPS cells (Muse-iPS cells), and colonies originat-
ing from non-Muse cells (non-Muse colonies) were unlike
human ES or iPS cells in their morphology and failed to
establish iPS cells. iPS cells-derived from Muse cells
expressed not only Oct3/4, Sox2, and Nanog but also Rex1,
UTF1, TERT, Abcg2, Dnmt3b, and Cdx2. These cells
Fig. 1 Properties of Muse cells.
Muse cells can be collected
from cultured mesenchymal
cells (fibroblasts, bone marrow-
MSCs, or fat-MSCs) and
mesenchymal tissues (adipose
tissue, dermis, and bone marrow
aspirates) as cells double-
positive for SSEA-3 and
CD105. After isolating Muse
cells by FACS, single Muse
cells cultured in suspension
(single cell suspension culture)
generate characteristic clusters
that express markers related to
pluripotency [alkaline
phosphatase (ALP), Nanog,
Sox2, Oct3/4, SSEA-3]. When
cell clusters were transferred
onto gelatin culture and
spontaneous differentiation was
induced, cells with endodermal-
(alpha-fetoprotein ? cells),
ectodermal-
(neurofilament ? cells), and
mesodermal- (desmin ? cells)
lineage were observed. We
confirmed that Muse cells
continued to self-renew up to
the fifth generation, indicating
that they are pluripotent
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differentiated into endodermal-, ectodermal-, and mesoder-
mal-lineage cells in vitro, and formed teratomas after injection
into immunodeficient mouse testes [30].
It is easy to understand that Muse cells that already show
pluripotency are more susceptible than non-Muse cells to
becoming iPS cells, but the more important question is why
none of the non-Muse cells developed into iPS cells. Indeed,
non-Muse cell-derived colonies did not express the funda-
mental transcriptional regulators for pluripotent stem cells,
such as endogenous Oct3/4, endogenous Sox2, or Nanog, but
nor did they express Rex1, Abcg2, Dnmt3b, or Cdx2, which
have been known to indicate the reprogramming state of
colonies [71]. Chan et al. [71] reported that colonies gener-
ated during iPS cell generation can be divided into type I, II,
and III colonies: type I colonies, which do not express Rex1,
Abcg2, Dnmt3b, and Cdx2, do not develop into iPS cells and
but remain in the incompletely reprogrammed state; type II
colonies, which do not express Rex1, Abcg2, or Dnmt3b, but
do express Cdx2, occasionally spontaneously transit to iPS
cells; and type III colonies, which express these four genes
and are identified as iPS cell colonies. In this context, non-
Muse cell-derived colonies negative for Rex1, Abcg2,
Dnmt3b, and Cdx2 correspond to type I colonies that stay
arrested at an early stage of iPS cell generation and thus do
not develop into iPS cells [30] (Fig. 2).
The inability of non-Muse cells to respond to the
Yamanaka factors could also be seen in the methylation
state of the promoter regions of Nanog and Oct3/4. In the
naive state, the Nanog and Oct3/4 promoter regions are
more methylated in non-Muse cells than in Muse cells. In
Muse cells, however, those partly methylated promoter
regions become completely demethylated when they
develop into iPS cells. On the other hand, such demethyl-
ation of the promoter regions of Nanog and Oct3/4 is never
observed in non-Muse cell-derived colonies [30]. Those
phenomena were all repeated using a single polycistronic
Oct3/4–Klf4–Sox2–c-Myc–GFP-expressing viral vector
encoding all four factors, confirming that all of the above
phenomena are not caused by unsuccessful transduction of
one or more of the four retroviral vectors encoding Oct3/4,
Sox2, Klf4, and c-Myc [30].
Gene expression profiles provide information about cell
responsiveness to the Yamanaka factors. As for genes related to
pluripotency, the ‘‘expression level’’ is lower in naive Muse
cells than in Muse-iPS cells, but the ‘‘expression pattern’’,
namely the repertoire of genes expressed, is nearly the same
between naive Muse cells and Muse-iPS cells. In contrast,
naive non-Muse cells do not express genes related to pluripo-
tency, and neither the expression level nor pattern show
substantial changes even after receiving the Yamanaka factors,
namely in non-Muse colonies (Fig. 3). Genes related to cell-
cycle progression were mostly upregulated in Muse cell-
derived iPS cells as compared with naive Muse cells. This is
consistent with the fact that naive Muse cells have lower telo-
merase activity and do not form teratomas after transplantation
into immunodeficient mouse testes, while Muse-iPS cells
formed teratomas. In non-Muse cell-derived colonies, some of
the genes related to cell-cycle progression were upregulated
compared with those in naive non-Muse cells, but the upreg-
ulation was marginal and not as extensive as in Muse-iPS cells
[30] (Fig. 3).
What kind of ability does the Yamanaka factors confer
on the cells?
The most noteworthy observation of these gene expression
patterns is that, regardless of whether the cells are Muse or
Fig. 2 When human fibroblasts
were separated into Muse and
non-Muse cells and each
population subjected to iPS cell
generation, iPS cells are
generated only from Muse cells
and never from non-Muse cells.
The properties of each cell
population are shown in the
boxes
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non-Muse cells, the expression pattern of genes related to
pluripotency is not altered by introduction of the Yama-
naka factors (Fig. 3). In other words, introduction of the
Yamanaka factors does not alter the cell state in terms of its
differentiation ability. Although Muse cells express the
pluripotency-related genes, it is reasonable that the gene
expression profile in adult human dermal fibroblasts will be
as same as that in non-Muse cells because the ratio of Muse
cells in dermal fibroblasts is only several percent [30], so
that the signal from Muse cells is masked by the vast
majority of non-Muse cells (Fig. 3). When the pluripotency
gene expression pattern of fibroblasts changed to that of
iPS cells, then it seems that introducing the Yamanaka
factors brought terminally differentiated cells back to the
cell state resembling that of the inner cell mass cells. The
differences in the results of Muse and non-Muse cell
experiments clearly indicate that this did not happen in
human fibroblasts.
Apart from these issues, the question of how Muse cells
become iPS cells remains to be clarified. Muse cells are
originally non-tumorigenic, but when they become iPS
cells, they newly acquire tumorigenic proliferation activity
while retaining their pluripotency. It is noteworthy that
Nanog and Oct-4 accelerate cell-cycle progression in plu-
ripotent stem cells such as ES cells [72, 73]. It is also
reported that over-expression of Oct4 caused hyperplasia in
the new-born mice [74]. Thus, it is possible that the gen-
eration of iPS cells from Muse cells requires a much higher
expression of critical transcription factors including pluri-
potency markers that may lead to the activation of genes
related to cell-cycle progression, which is followed by
further increases in the pluripotency marker expression
Fig. 3 Gene expression pattern in Muse, Muse-iPS (M-iPS), non-
Muse, and non-Muse colonies (non-Muse col). The expression pattern
of pluripotency markers in Muse cells and Muse-iPS was almost the
same, but expression level was higher in Muse-iPS cells than in naive
Muse cells (green). Neither Muse nor non-Muse cells showed a
change in the expression pattern of pluripotency markers even after
receiving the Yamanaka factors (orange). While naı¨ve fibroblasts are
known to contain Muse cells, the expression pattern and level of
pluripotency markers in the fibroblasts as a whole takes on the pattern
of non-Muse cells (purple). Genes related to cell cycle progression
did not largely differ between Muse and non-Muse cells (blue), but
they were upregulated when Muse cells became Muse-iPS cells
(yellow). (Modified version of table 1 in Ref. [30])
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levels. Such synergistic effects may result in higher
expression levels of genes related to pluripotency as well as
to cell-cycle progression in Muse cell-derived iPS. The
characters of Muse cells in terms of homogeneity and their
derivation from different mesenchymal sources (such as
skin and bone marrow) have not been fully elucidated, so
that the responsiveness of each Muse cell to the Yamanaka
factors should be clarified as a future issue.
In the framework of Muse and non-Muse cells, human
fibroblasts can be divided into two populations: cells that
primarily contribute to iPS cell generation and those that do
not. These results demonstrate that the human fibroblast
system fits into the elite model of iPS cell generation.
Further studies will clarify the potential of this system to
generate iPS cells from other tissues and cell types.
The necessity for unified criteria to identify iPS cells
Initially, iPS cells were reported to be generated from mice
and human fibroblasts with very low efficiency, nearly
0.001 %, [1, 2], but many recent attempts have been made
to improve the generation efficiency. For example, com-
bining gene introduction with the use of reagents such as
valproic acid, or inhibitors for TGF-beta, MAPK/ERK, or
suppression of p53 is reported to increase the efficiency of
iPS cell generation [75–77]. More recently, a replication-
defective and persistent Sendai virus vector containing
Oct4/Sox2/Klf4/c-Myc induced iPS cell from mouse pri-
mary fibroblasts with an efficiency of *1 %, as estimated
by green fluorescent protein expression driven by the Na-
nog promoter [78]. Similarly, replacing c-Myc with Glis1
increased iPS cell generation from human fibroblasts with
an efficiency of *0.16 %, also based on Nanog promoter
activity [79]. As for the use of valproic acid, the efficiency
in mouse embryonic fibroblasts was increased up to
*2–3 %, based on Oct4-green fluorescent protein quanti-
fication [80]. Despite these efforts, however, the generation
efficiency is still far from being very high. Even in the case
of Muse cells, generation efficiency is only 0.03 %, albeit
counted strictly based on the expression of Nanog,
endogenous Oct3/4, and Sox2 as well as Rex1, Abcg2,
Dnmt3b, and Cdx2. This efficiency corresponds to 30 times
greater efficiency than naive fibroblasts [30].
As evidenced by these reports, the primary problem in
iPS cell research is that the criteria for iPS cell generation
differs among reports; some reports calculate generation
efficiency based only on ALP staining, whereas others base
generation efficiency on the expression of a single pluri-
potency marker. Because of the current lack of unified
criteria to identify the generation of iPS cells, the reported
generation efficiencies cannot be compared with each
other. In fact, not all colonies positive for ALP staining are
iPS cells, and likewise, not all colonies that are positive for
the expression of a reporter gene product driven by only by
a single pluripotency-related gene promoter such as Nanog
or Oct3/4 meet the strict criteria for iPS cells [70, 81].
Previously, gene expression analyses in live images and
quantitative PCR were performed both in colonies resem-
bling and colonies not resembling ES cells and revealed
that the expression of Nanog or Oct3/4, or positive reaction
for ALP, occur in various kinds of colonies other than iPS
cells, and thus suggest that both factors are unreliable for
the identification of iPS cells [71, 82]. In addition, tissue
stem cells are occasionally positive for Oct3/4- or Nanog,
implying that a single marker expression of these genes
will also not indicate the cells in the pluripotent state [38,
39, 66]. These findings indicate that the calculation of iPS
cell generation based on the single expression of Oct3/4 or
Nanog will likely overestimate the number of iPS cells.
Unified and reliable criteria to identify iPS cells must be
firmly established.
Perspectives
Many reports have focused on the interpretation of the
output of iPS cell generation, but understanding the
properties of the original starting cell population for
generating iPS cells is important for understanding their
generation mechanism. Indeed, when the emergence of
iPS cells is unforeseeable, it seems that all cells have the
potential to become iPS cells and that iPS cells are sto-
chastically generated by coincidence combined with an
exquisite balance of intrinsic factors. On the other hand,
pluripotent cells such as Muse cells are recognized among
the original cell population, and iPS cells are exclusively
generated from these cells; thus, we now recognize that
the stochastic model is not the only viable theory of iPS
cell generation. Therefore, we must turn our attention to
the heterogeneity and diversity of the original cell popu-
lation. The major publication regarding the mechanism of
iPS cell generation and characterization is summarized in
Table 1.
As it now stands, the therapeutic use of iPS cells in
patients is severely limited by the fact that iPS cells are
immortal with the ability to cause tumors. Even if iPS cell-
derived cells undergoing differentiation have a low risk of
tumorigenesis, there are currently no realistic methods for
resolving the issue of tumorigenesis. Thus, it is too difficult
to detect and eliminate all the undifferentiated tumorigenic
cells among the large number of iPS cells before thera-
peutic applications. In addition, the potential dangers posed
by the uncontrolled and unstable genomes of iPS cells have
been recently demonstrated by the analysis of several lines
of ES and iPS cells [83].
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Table 1 Summary of published articles that relate to the mechanism of iPS cell generation and characterization
Ref. No. Title Summary Related subjects
[4] Cell type of origin influences the
molecular and functional properties of
mouse induced pluripotent stem cells
iPS cells from mouse fibroblasts,
hematopoietic and myogenic cells
exhibit distinct transcriptional and
epigenetic patterns. Cellular origin
influences the in vitro differentiation
potentials of iPS cells
Tissue origin and
differentiation potential
[5] Induced pluripotent stem cells and
embryonic stem cells are distinguished
by gene expression signatures
Genome-wide data suggested that the
iPSC signature gene expression
differences are due to differential
promoter binding by the
reprogramming factors. Epigenetic
memory of the donor tissue could be
reset by serial reprogramming
Epigenetic memory
[6] Epigenetic memory and preferential
lineage-specific differentiation in
induced pluripotent stem cells derived
from human pancreatic islet beta cells
The pancreatic islet beta cell-derived iPS
cells maintained open chromatin
structure at key beta-cell genes,
together with a unique DNA
methylation signature. Those iPS cells
demonstrated an increased ability to
differentiate into insulin-producing
cells compared with ES cells
Tissue origin and
differentiation potential
[7] Incomplete DNA methylation underlies a
transcriptional memory of somatic cells
in human iPS cells
A systematic comparison of iPS cells
generated from hepatocytes, skin
fibroblasts and melanocytes showed
that iPS cells retain transcriptional
memory of the original cells. The
persistent expression of somatic genes
can be partially explained by
incomplete promoter DNA methylation
Incomplete promoter DNA
methylation
[8] Epigenetic memory in induced
pluripotent stem cells
IPS cells harbor residual DNA
methylation signatures characteristic of
their somatic tissue of origin, which
favors their differentiation along
lineages related to the donor cell. The
differentiation and methylation of
nuclear transfer-derived pluripotent
stem cells were more similar to ES
cells
Epigenetic memory
[9] Donor cell type can influence the
epigenome and differentiation potential
of human induced pluripotent stem
cells
As a consequence of both incomplete
erasure of tissue-specific methylation
and aberrant de novo methylation,
umbilical cord blood- and neonatal
keratinocyte-iPS cells were distinct in
genome-wide DNA methylation
profiles and differentiation potential,
implying that iPS cells retain




[10] Cancer-related epigenome changes
associated with reprogramming to
induced pluripotent stem cells
Cancer-related epigenetic abnormalities
arise early during reprogramming and
persist in iPS cell colonies. These
include hundreds of abnormal gene
silencing events, patterns of aberrant
responses to epigenetic-modifying
drugs resembling those for cancer cells
Epigenetic abnormalities
[11] Immunogenicity of induced pluripotent
stem cells
In contrast to ES cells, abnormal gene
expression in some cells differentiated
from iPS cells can induce T cell-
dependent immune responses in
syngeneic recipients
Immune responses
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Together, these issues reveal the strong need for a basic
understanding of the iPS cell-generation mechanism. At
any rate, the questions of what are iPS cells and how are
they generated remain crucial issues to be resolved, and
understanding the basic characteristics of iPS cells will
advance the studies of these cells and their application.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
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